|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Mar 31, 2006. Impairment of Investments
During 2005, investment impairment charges of $31.7 million
(2004: $74.7 million) reflect other-than-temporary
impairments to the value of a number of investments, primarily
in privately-held biotech companies. Impairments in 2005 relate
primarily to Targeted Genetics Corporation (Targeted Genetics)
of $12.4 million, Iomai of $5.0 million and
Glycogenesys, Inc. (Glycogenesys) of $3.1 million. Included
in the 2004 charge were impairments related to investments in
Athersys, Inc. of $17.8 million, Beyond Genomics, Inc. of
$7.6 million, Medisys, plc of $6.0 million, Digital
Gene Technologies, Inc. of $6.0 million, and Emisphere of
$5.7 million.
This excerpt taken from the ELN 20-F filed Mar 30, 2006. Impairment
of Investments
During 2004, impairment charges of $71.8 million (2003:
$87.5 million) reflect
other-than-temporary
impairments to the value of a number of investments, mainly in
privately-held biotech companies.
| EXCERPTS ON THIS PAGE:
|
| |||||||
